TScan Therapeutics (TCRX) Other financing activities (2020 - 2025)

TScan Therapeutics (TCRX) has 6 years of Other financing activities data on file, last reported at $9000.0 in Q4 2025.

• On a quarterly basis, Other financing activities rose 100.01% year-over-year to $9000.0 in Q4 2025; TTM through Dec 2025 was $200000.0, a 88.35% decrease from a year earlier, with the FY2025 full-year figure at $200000.0, down 88.35% from the prior year.
• Other financing activities for Q4 2025 stood at $9000.0, up from -$9000.0 in the prior quarter.
• Over the last five years, Other financing activities for TCRX reached as high as $127.8 million in Q3 2024 and fell as low as -$126.6 million in Q4 2024.
• Historically, Other financing activities has averaged -$5.0 million across 5 years, with a median of $65500.0 in 2021.
• Across the five-year window, Other financing activities tumbled 132863.77% in 2023 and surged 168297.37% in 2024, its largest moves.
• Year by year, Other financing activities stood at $120000.0 in 2021, then sank by 42.5% to $69000.0 in 2022, then tumbled by 132863.77% to -$91.6 million in 2023, then plunged by 38.15% to -$126.6 million in 2024, then soared by 100.01% to $9000.0 in 2025.
• Per Business Quant data, the three most recent Other financing activities figures were $9000.0 in Q4 2025, -$9000.0 in Q3 2025, and $75000.0 in Q2 2025.